# OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

> **NCT01955200** · PHASE4 · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 1724 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Cilostazol
- **DRUG:** Ticagrelor
- **DRUG:** Clopidogrel
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT01955200
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-05
- **Primary completion:** 2016-12-26
- **Final completion:** 2017-11-28
- **Target enrollment:** 1724 (ACTUAL)
- **Last updated:** 2020-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955200, "OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01955200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*